Clinical trials
Recruiting Sjogren's Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 12 |
| 2025 | 15 |
| 2026 | 13 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 56 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 3 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 3 |
| Peking Union Medical College Hospital | 3 |
| Centre Hospitalier Universitaire de Saint Etienne | 2 |
| Essen Biotech | 2 |
| Novartis Pharmaceuticals | 2 |
| Peking University People's Hospital | 2 |
| Peking University Third Hospital | 2 |
| Taipei Veterans General Hospital, Taiwan | 2 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sjogren's Syndrome | 56 |
| Lupus Erythematosus, Systemic | 22 |
| Scleroderma, Systemic | 18 |
| Arthritis, Rheumatoid | 14 |
| Myositis | 13 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 11 |
| Autoimmune Diseases | 11 |
| Antiphospholipid Syndrome | 7 |
| Scleroderma, Diffuse | 6 |
| Arthritis, Psoriatic | 5 |
Trials
Showing 76 to 56 of 56. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.